SK pharmteco
Andy Fenny has a significant amount of work experience, with their most recent position being the Chief Commercial Officer (CCO) at SK pharmteco since September 2023. Prior to that, they held several roles at FUJIFILM Diosynth Biotechnologies, including Chief Business Officer from February 2018 to September 2023. Before joining FUJIFILM Diosynth Biotechnologies, they worked at MSD Biologics as a Senior Programme Manager from February 2010 to March 2011, and at Avecia as a Senior Programme Manager from 2002 to 2010. Overall, Andy Fenny has a strong background in program management and business planning within the biotechnology and pharmaceutical industry.
Andy Fenny completed a Bachelor of Science in Cell/Cellular and Molecular Biology from The University of Huddersfield, from 1998 to 2002.
This person is not in any offices
SK pharmteco
Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group.